Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.94, $0.02 worse than the analyst estimate of $1.96. Revenue for the quarter came in at $6.77 billion versus the consensus estimate of $6.6 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2021 EPS of $7.95-$8.05, versus the consensus of $6.80.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.